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ABSTRACT - Fibrodysplasia ossificans progressiva is a rare genetic disease characterized by widespread
soft tissue ossification and congenital stigmata of the extremities. We report on a male child followed for ten
years since the age of 3 years and 9 months, when the diagnosis was made. He was born with bilateral hypoplasic
hallux valgus and ventricular septal defect, corrected by transsternal approach when 32 months old. Restriction
of neck mobility followed and foci of ectopic ossification appeared. Four crises of disease exacerbation were
treated with oral prednisone and/or other antiinflammatory drugs. Sodium etidronate 5 to 10 mg/kg/day was
prescribed intermittently during about six years but was discontinued due to osteopenia. The disease course
has been relentless, with severe movement restriction including the chest wall. A review showed few similar
case reports in the Brazilian literature. We revisit the criteria for diagnosis and the essentials of management
and treatment.
KEY WORDS: fibrodysplasia ossificans progressiva, myositis ossificans, muscle biopsy, rigid spine,
99mTc-MDP scan, etidronate treatment.
Fibrodisplasia ossificante progressiva: relato de caso
RESUMO - Fibrodisplasia ossificante progressiva é uma doença genética rara, caracterizada por ossificação
disseminada em tecidos moles e estigmas congênitos nas extremidades. Relatamos sobre uma criança do sexo
masculino, branca, que vem sendo acompanhada desde seus 3 anos e 9 meses quando diagnosticamos a doença.
Nascida com halux valgo hipoplásico bilateral e defeito do septo interventricular, submeteu-se a correção cirúrgica
através de esternotomia, aos 32 meses de vida. Seguiram-se progressiva restrição de movimentos cervicais e
aparecimento de nódulos duros e dolorosos em regiões paravertebrais cérvico-torácicas. Em dez anos, assistimos
a quatro episódios bem definidos de exacerbação da doença, com acréscimos de ossificação ectópica. Nessas
ocasiões, prescrevíamos prednisona oral e/ou antiinflamatórios não hormonais. Etidronato de sódio, 5 a 10 mg/
kg/dia, foi utilizado em períodos de dois ou três meses, com intervalos de dois meses, durante seis anos. Osteopenia
obrigou-nos a interromper o uso do quelante. A evolução tem sido inexorável, com limitação intensa de movimentos
torácicos e corpóreos. A revisão da literatura brasileira revelou poucos casos semelhantes. Enfatizamos os critérios
para diagnóstico e princípios básicos de tratamento.
PALAVRAS-CHAVE: fibrodisplasia ossificante progressiva, miosite ossificante, biópsia muscular, espinha
rígida, cintilografia com MDP-99mTc, tratamento com etidronato.
Fibrodysplasia ossificans progressiva (FOP) is a rare, autosomal dominant disease1-3 affecting
all ethnic backgrounds4. It is particularly disabling in children and is characterized by two cardinal
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features: heterotopic progressive osteogenesis and congenital abnormalities of the great toes5,6. The
disease should be familiar to neonatologists, pediatricians, neurologists, orthopedic clinicians and
surgeons, rheumatologists and ancillary personnel engaged in the diagnosis and management of
neuromuscular conditions.
The term fibrodysplasia ossificans progressiva is preferred to myositis ossificans5 because
ectopic osteogenesis occurs in the connective tissue within muscles, fasciae, ligaments, tendons and
joint capsules, rather than in the muscle fibers themselves. These may show nonspecific, possibly
secondary pathological changes6.
Recently, FOP has been considered a connective tissue disorder due to overexpression of a
bone morphogenetic protein, BMP 4 7,8. Since curative therapy is not available, management is
based on the principle of primum non nocere, particularly at preventing abnormal ossification5.
Therefore, an increased awareness of the disease among clinicians is of great importance.
We report on a patient with FOP followed up for ten years who used sodium etidronate on an
intermittent schedule. We revisit the criteria for diagnosis, treatment and main rules for management.
Emphasis is placed on the adverse effects of simple surgical procedures, such as muscle biopsy,
which may propitiate ectopic ossification and is not contributory for the diagnosis.
CASE
A caucasian boy, the first child of young, healthy, non-consanguineous parents (father, 23; mother, 20
years old), was born in September 1985 by caesarean section after an uneventful full-term gestation. The parents
do not have any obvious clinical skeletal malformation and a younger sister of the patient is reported as normal.
The neonate was considered in good condition, with 53 cm and 3,800 g. An orthopedic consultation was
requested because of malformation of the great toes. A plain roentgenogram of the feet was done and the child
discharged. Routine pediatric follow up elsewhere revealed cardiac murmur and delayed somatic development.
Although cyanosis was not a complaint, a congenital interventricular septal defect was corrected by transsternal
approach in May 1988 (at the age of 2 years and 8 months). Psychomotor development was always within normal
limits. He was first seen at the Neuromuscular Clinic, UNICAMP in June, 1989. The parents observed progressive
difficulty in the child’s neck extension and, in the last six months, appearance of several hard nodules in the cervical
and dorsal regions. Some were painful and the overlying skin was erythematous. Examination revealed a cooperative,
intelligent boy with restricted mobility during walking, sitting and standing caused by a rigid kyphoscoliotic spine.
All paraspinal muscles were hard on palpation. There were several nodular masses fixed to deep planes and scattered
over the back (Fig 1). Abduction of the shoulders and mobility of the hips were severely restricted. Clinodactyly of
both fifth fingers (Fig 1) and bilateral short hallux valgus (Fig 1) were also observed.
Hemogram, erythrocyte sedimentation rate, serum calcium, phosphorus, alkaline phosphatase, creatine
phosphokinase, alanine and aspartate transaminases, routine urinalysis, urine calcium and phosphorus, and
creatinine clearence were within normal limits. Alkaline phosphatase ranged from normal to mildly elevated
during evolution. A recent 99mTc-MDP scan (Fig 2) showed areas of abnormal uptake in the soft tissue of the left
lumbar paravertebral region, right posterior chest wall and posterior aspect of the right arm, consistent with soft
tissue calcifications with variable degrees of uptake. Several foci of increased uptake were also demonstrated
adjacent to the ribs and lateral aspects of the thoracic spine, corresponding to the palpable nodules of heterotopic
calcification. The intense tracer uptake in the proximal third of the right femur was in agreement with the patient’s
right hip ankylosis. A focal area of mild uptake in the distal third of the left fibula was reported as the site of
possible trauma or microfracture due to osteomalacia. The other sites of heterotopic bone formation were not
observed probably because of complete maturity of the process of ossification in those regions.
Follow up from 1989 to 1999 documented four periods of exacerbation, heterotopic ossification appearing
in the dorsal thoracic region, inferior right abdomen, biceps and medial left arm and forehead, the latter two after
local trauma. All episodes were accompanied by local inflammatory signs, restriction of movement and pain and
were treated by oral prednisone and/or nonsteroidal antiinflammatory drugs. For about six years since August 1989
sodium etidronate (ethane-1-hydroxy-1,1-diphosphonate) was prescribed in oral doses of 5 to 10 mg/kg/day for
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Fig. 1 (left) Dorsal view of patient at age 13. (above) Hands to show bilateral clinodactyly of the fifth
finger. (below) Typical deformity of the feet (bilateral short hallux valgus).
Fig 2. Whole body and spot images of the bone scan, with mild abnormal tracer uptake in the soft tissues of the
left lumbar paravertebral region, posterior chest wall, right arm and right hip (soft tissue calcification).
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periods of two or three months intercalated by two month drug free intervals. Diphosphonate was definitely
withdrawn in 1995 because osteopenia was detected by bone densitometry.
Presently the patient is ambulatory, but with severe limitations in axial movements due to rigidity of the
whole spine. Shoulders and hips show bilateral ankylosis. Chest expansion is greatly restricted as documented
by pulmonary function tests. Cardiac function is normal.
DISCUSSION
FOP should be diagnosed as early as possible and non-invasively, based upon history, clinical
and radiological findings5. The mainstay of diagnosis is bilateral great toe anomaly present from
birth, reported in 79 to 100% of patients in representative series9-12. The most characteristic deformity
is microdactyly of both halluces due to a single phalanx in valgus position9,10 (type I deformity
according to Connor and Evans11). Three other subtypes of malformed big toes can be diagnosed up
to the second decade11, and this is where radiologic examination is especially important. Isolated
congenital hallux valgus (i.e. not as part of FOP) is much rarer than FOP itself5. Th refore, the
finding of congenital hallux valgus must raise the possibility of FOP so that management should be
early and adequate.
Hand malformation is generally associated with, and proportional to the severity of hallux
dysmorphism, and indeed is not seen in its absence10. The most frequent anomalies are short first
metacarpal and brachymesophalangy of the fifth finger with clinodactyly10.
Ectopic ossification, another hallmark of disease, occurs lifelong, with records of its initial
appearance at the mean age of three11 or five years13. In almost all patients, onset of the lesions was
noted under 159-13. Ectopic ossification follows a well defined pattern, the axial body being
compromised first and most. Shoulder and hip regions are affected more than distal segments of the
limbs9. Deafness and baldness have been reported in up to one fourth of the cases, while mental
retardation is rare11.
Exacerbation of FOP may occur spontaneously or be precipitated by trauma, such as
intramuscular injections including vaccines14, local anesthesia, specially troncular block near the
temporomandibular joint11, muscle biopsy6 and careless venepuncture11. Biopsy of calcified nodules
is to be avoided if the diagnosis of FOP is clear on clinical and radiological grounds (foot and hand
stigmata). Biopsy may result in recurrent ossification of the site, sometimes worse than the original
lesion11. Another clinical expression of FOP is acute or chronic limb swelling, defined as an
enlargement of the limb circumference at one or more locations with increased tissue turgor, the
pathogenesis of which is multifactorial15.
In the present case, cardiac surgery was followed on a short term by increased limitation of
neck flexion. This is to the best of our knowledge the first patient with FOP reported who was
submitted to this procedure. Patients undergoing other types of surgical intervention such as abdominal
hysterectomy, appendicectomy, herniorrhaphy and excision of fibroadenomas of the breast did not
present ossification11.
Routine laboratory tests including calcemia and phosphatemia are usually normal or non
contributory in FOP. Roentgenograms may aid in documenting minor osseous dysmorphism. Bone
scintigraphy with 99mTc-MDP may demonstrate early the heterotopic ossification and aid in the
assessment of the extent and progression of the disease16,17.
So far no effective treatment for FOP is known. All management is conservative and based
on the principle of primum non nocere, that is, of avoiding conditions potentially provocative of
abnormal ossification5. Several types of treatment have been tried18. Administration of calcium
chelants such as sodium etidronate have been proposed since 1969 with variable results19. In our
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patient the drug was given over some five years on an intermittent schedule in order to delay
osteopenia. However, during treatment the nodules did not stop appearing and bone demineralization
did become a significant side effect, although in the literature it has been described only with higher
doses19. Inflammatory signs preceding ossification were generally less severe when corticosteroid
was used and indeed the drug is recommended per os on these occasions. In acute flareups, oral
corticosteroids and intravenous etidronate were used simultaneously in an open trial with promising
results. Controlled trials are thus encouraged20.
The phenotype and natural history of FOP are by now so well defined that differential
diagnosis is limited. Other disorders of ectopic ossification may be considered, such as Albright
hereditary osteodystrophy, pseudomalignant heterotopic ossification, progressive osseous
heteroplasia and even osteosarcoma21-23.
In the recent Brazilian literature, three cases fulfill clinical and radiologic criteria for FOP24,25.
In the case of Tonholo-Silva et al.26, although there were ectopic ossifications they did not appear to
be axial, and the characteristic skeletal stigmata of FOP were not mentioned. Garcia Filho et al.27
studied 25 cases of ‘heterotopic ossification’ including one of ‘progressive myositis ossificans’
which may represent an instance of FOP.
It is hoped that the recent surge of knowledge on molecular genetics will lead to better
understanding of the pathogenesis and to effective treatment for FOP.
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